Mycobacterium tuberculosis is a notorious pathogen that continues to threaten human health. Rv0164, an antigen of both T-and B cells conserved across mycobacteria, and MSMEG_0129, its close homolog in Mycobacterium smegmatis, are predicted members of the START domain superfamily, but their molecular function is unknown. Here, gene knockout studies demonstrate MSMEG_0129 is essential for bacterial growth, suggesting Rv0164 may be a potential drug target. The MSMEG_0129 crystal structure determined at 1.95 A reveals a fold similar to that in polyketide aromatase/ cyclases ZhuI and TcmN from Streptomyces sp. Structural comparisons and docking simulations, however, infer that MSMEG_0129 and Rv0164 are unlikely to catalyze polyketide aromatization/cyclization, but probably play an irreplaceable role during mycobacterial growth, for example, in lipid transfer during cell envelope synthesis.
Tuberculosis (TB) is an ancient disease caused by
Mycobacterium tuberculosis that remains a major threat to public health. One third of the world's population is estimated to be latently infected with M. tuberculosis, with 10.4 million new TB cases and 1.7 million TB deaths in 2016 [1] . The only licensed anti-TB vaccine, the Bacillus Calmette-Guerin vaccine, however, does not provide sufficient protection against adult pulmonary TB [2] , and resistance to first-/second-line anti-TB drugs in M. tuberculosis poses a severe challenge to global TB control [3] . More effective diagnostics, vaccines, and new drugs are thus urgently required to fight against TB.
Rv0164 is a conserved protein in the mycobacteria [4] and in vitro transposon mutagenesis has shown it to be an essential gene for M. tuberculosis growth [5] . Interestingly, this protein, comprised of 161 amino acids, has been identified as both a T-cell antigen with Abbreviations ARO, aromatase; CYC, cyclase; PKS, polyketide synthase; TB, tuberculosis.
the ability to induce IFN-c production in human peripheral blood mononuclear cells [6] [7] [8] , and as a B-cell antigen that has potential to serve as a biomarker in serological diagnosis of TB [9, 10] . Rv0164 is thus not only a potential pharmacological target for anti-TB drug design but also a candidate immunogen for vaccine development and rapid diagnosis of TB.
Based on amino acid sequence analysis, Rv0164 is predicted to be a member of the steroidogenic acute regulatory protein-related lipid transfer (START) domain superfamily (IPR023393) defined in InterPro [11] , characterized by a consensus a/b helix-grip fold and a deep hydrophobic pocket for ligand binding [12, 13] . This superfamily covers a plethora of proteins with various biological functions in prokaryotes and eukaryotes, for example, lipid transport proteins in mammals [14] , phytohormone receptors in plants [15, 16] and polyketide cyclases/aromatases (CYC/ ARO) in bacteria [17, 18] . Proteins containing a START domain can bind ligands and may or may not have enzymatic activity [19] . The M. tuberculosis genome encodes 18 proteins with predicted START domains [19] , but their structures and functions remain unknown. Sequence alignment suggests that Rv0164 may be a remote homolog to the HMM PF03364 protein family in Pfam [20] , a family that contains both polyketide cyclases/dehydrases and lipid transport proteins.
Polyketides, natural products with multiple biological and pharmacological activities, are synthesized in bacteria, fungi, and plants by polyketide synthases (PKSs), enzymes that are classified into three types based on their molecular architecture [21] . Type I PKSs are large multifunctional polypeptides consisting of multiple catalytic domains [22] , Type II PKSs are complexes composed of multiple discrete enzymes that are typically monofunctional [23] , and Type III PKSs are homodimeric enzymes with a single catalytic domain [24] . Of these, only Type II PKSs contain an enzyme with polyketide ARO/CYC activity.
Type II PKSs are mainly distributed in the actinomycetes and iteratively synthesize polyketide chains from a simple starting substrate such as malonyl-CoA, attaching a 2-4 carbon extender at each cycle of chain elongation [21] . Linear PK chains are transformed into aromatic polyketides by a regiospecific cyclization of linear poly-b-ketone intermediates catalyzed by ARO/ CYC, giving rise to aromatic polyketides with various pharmacological properties including antibiotic, antiparasitic, and antitumor activities [25, 26] . These aromatic polyketides show an impressive diversity of molecular structures. The substrates of ARO/CYCs vary among bacterial species even though all ARO/CYCs display a similar fold. For example, the preferred substrates of Streptomyces sp. Type II PKS enzymes ZhuI and TcmN differ in the number of carbon atoms in the PK chains, resulting in products with different first-ring cyclization patterns: C7-C12 and C9-C14, respectively [27, 28] .
The homolog of Rv0164 in Mycobacterium smegmatis (a nonpathogenic model organism for M. tuberculosis), MSMEG_0129 (144 amino acids), shares 59% sequence identity with Rv0164. Rv0164 and MSMEG_0129 share low sequence identity (~19%) with ZhuI and TcmN, both of which adopt a helixgrip fold containing a seven-stranded antiparallel b-sheet, a long C-terminal a-helix and two small helices that form a deep interior pocket for poly-bketone intermediate binding [18, 29] . Molecular docking of potential polyketide intermediates to these enzymes suggested that the binding and cyclization pattern of polyketide substrates may be determined by the size, shape and amino acid composition of the interior pocket [18, 29] .
As currently annotated, M. tuberculosis encodes approximately 21 Type I PKSs and three Type III PKSs [30] , most of which are involved in the biosynthesis of complex mycobacterial cell envelope lipids critical for virulence [31, 32] . For example, Pks13, a Type I PKS, is a key enzyme in the last step of mycolic acid biosynthesis [33] , and is considered to be a promising drug target against drug-resistant M. tuberculosis [34] . Type II PKSs have not yet been identified in mycobacteria. In order to investigate the biological role of MSMEG_0129 and its homologs in mycobacteria, we constructed a MSMEG_0129 knockout strain in M. smegmatis, determined the crystal structure of MSMEG_0129 and analyzed its potential substratebinding pocket by structural comparisons and docking. Data obtained infer that MSMEG_0129, and Rv0164 by extension, are likely not enzymes that catalyze polyketide cyclization and aromatization, but nonetheless play an irreplaceable role, for example, in lipid transfer, in bacterial envelope synthesis.
Materials and methods

Media and growth conditions
Mycobacterium smegmatis strains were cultured in Middlebrook 7H9 liquid culture medium (Difco, Baltimore, MD, USA) supplemented with 0.5% glycerol and 0.05% Tween 80 at 37°C. When required, 50 lgÁmL À1 hygromycin or 25 lgÁmL À1 kanamycin were added to Middlebrook 7H10
plates for colony isolation. Plasmids and primers used in this study are listed in Table S1 .
Conditional knockout of the MSMEG_0129 encoding gene
The PCR-amplified msmeg_0129 gene from the genome of M. smegmatis mc2155 was inserted into pMindm between the EcoRV and PacI restriction sites. The resultant pMindm-MSMEG_0129 plasmid was later verified by DNA sequencing. An msmeg_0129 depletion strain was prepared using a specialized transduction procedure [35] . Briefly, pMindm-MSMEG_0129 was transformed into M. smegmatis mc2155 by electroporation to produce a merodiploid strain. The left (upstream) and right (downstream) homology sequences flanking msmeg_0129 were cloned into the two flanks of the sacB-hyg cassette in an intermediate plasmid (p0004s). The DNA fragment containing sacB-hyg flanked by the homology sequences was then subcloned into the phAE159 mycobacteriophage vector before it was transduced into the merodiploid strain containing pMindm-MSMEG_0129. Allelic exchange of sacB-hyg with msmeg_0129 in the genome of hygromycin-resistant transductants was subsequently confirmed by PCR.
Detection of MSMEG_0129 expression by western blotting
Mycobacterium smegmatis strains cultured in the presence of various concentrations of tetracycline (0-80 ngÁmL À1 )
were harvested at an OD 600 > 2.0 by centrifugation at 12 000 g for 10 min (4°C). Culture supernatants containing secreted proteins were filtered through a 0.22-lm filter, and concentrated using a centrifugal concentrator with a nominal cutoff of 3 kDa (Millipore, Shanghai, China). Harvested bacteria were lysed in PBS buffer containing 1 mgÁmL À1 lysozyme (Amresco, Sanborn, NY, USA) by ultrasonication on ice (10 cycles of 3-s pulses at 30% power with 3-s intervals). Insoluble debris was removed by centrifugation at 16 000 g for 30 min (4°C). Both secreted and cytosolic proteins were quantified using a BCA Protein Assay Kit (Pierce, Rockford, IL, USA). Approximately 30-lg samples of bacterial proteins were separated on a 12% SDS/polyacrylamide gel. GroEL was used as an internal reference. Western blotting was performed using a GroEL antibody (Santa Cruz Biotechology, Dallas, TX, USA), an anti-Histag antibody (Sigma-Aldrich, Shanghai, China), and an anti-mouse IgG secondary antibody conjugated with horseradish peroxidase (Promega, Beijing, China). Blot signals were visualized using a SuperSignal West Pico Trial Kit (Pierce) and radiographic film (Kodak, Beijing, China).
Protein expression and purification
A detailed method for recombinant MSMEG_0129 production and crystallization has been described in a separate report [36] . In brief, the nucleotide sequence encoding MSMEG_0129 was inserted into a modified pET-28a vector, in which the thrombin cleavage site was replaced by a TEV protease site, before protein production in Escherichia coli strain BL21(DE3). After cell lysis in buffer consisting of 20 mM Tris-HCl, pH 7.4, 300 mM NaCl, 10 mM imidazole, 5% (v/v) glycerol, the recombinant protein was purified using Ni 2+ affinity chromatography. After removal of the N-terminal His-tag through TEV protease cleavage, the protein was further purified by size exclusion chromatography using a Superdex 75 10/300 GL column (GE Healthcare, Uppsala, Sweden).
Crystallization and data collection
Crystallization trials were performed using the hangingdrop vapor-diffusion method at 16°C by mixing 1 lL purified protein solution (~5 mgÁmL
À1
) with an equal volume of reservoir solution. A single crystal of MSMEG_0129 was obtained under a condition of 2 M sodium formate, 0.1 M MES, pH 6.5 50 days after drop setup. X-ray data were collected on beamline BL19U1 at the Shanghai Synchrotron Radiation Facility (SSRF), China. Diffraction data were processed using XDS [37] .
Structure determination and refinement
The structure of MSMEG_0129 was determined by molecular replacement using PHENIX.ROSETTA_MR and the structure of ZhuI from Streptomcyes sp. R1128 (PDB entry: 3TFZ) [29] as a search model. The resultant model was automatically rebuilt using PHENIX.AUTOBUILD [38] , and then refined using PHENIX.REFINE [39, 40] with manual checking in COOT [41] . Detailed data collection and refinement statistics are summarized in Table 1 . All structural representations were generated using the molecular visualization program PYMOL [42] .
Docking simulations
The molecular docking tool GLIDE (MAESTRO version 9.0) was used to dock polyketide intermediate A20 or A24 to subunit A of MSMEG_0129 and two other known ARO/ CYC structures, namely TcmN (PDB entry 3TVQ) [18] and ZhuI (PDB entry 3TFZ) [29] . The Ligprep module of MAESTRO was used to generate low-energy conformers of A20 or A24. Initial protein models were prepared through bond order reassignment, deletion of crystallized solvent molecules, and addition of hydrogen atoms. Generation of ionized and tautomeric states for hetero groups and hydrogen bond assignment were performed using default parameters. To further alleviate steric clashes and refine the structure, an OPLS-2005 force field was applied to conduct energy minimization with an rmsd < 0. 30 A. Default box size was used in grid generation. The docking site was defined by the centroid of selected pocket residues F21, W27, Q55, and F83 in MSMEG_0129; W28, F88, F120, and N136 in TcmN; and Y27, V86, L135, and D146 in ZhuI. The docking simulation was conducted using the extra precision (XP) docking mode, and the top 10 binding conformations in terms of Gscores were retained for visual inspection. The conformation for binding analysis was selected based on clustered preferred conformations and protein-ligand interactions.
Results
MSMEG_0129 blocks cell division and is essential for M. smegmatis growth
The MSMEG_0129 encoding gene occurs in the same genomic context in M. smegmatis as its homologous gene encoding Rv0164 in M. tuberculosis [43] . To construct an msmeg_0129 knockout strain without disrupting adjacent genes, the sequence from nucleotides 118 to 915 in the destination ORF was substituted with a selective marker gene, the sacB-hyg cassette. No hygromycin-resistant colonies were obtained after several attempts using wild-type M. smegmatis mc2155, and we thus hypothesized that MSMEG_0129 may be an essential gene for M. smegmatis growth. To verify this, a merodiploid strain was constructed by introducing plasmid pMindm-MSMEG_0129 containing the full-length ORF of MSMEG_0129 under the control of a tetracycline-inducible promoter, the expression of plasmid-encoded MSMEG_0129, thus serving as a complement for the genomic msmeg_0129 knockout in this strain. As expected, hygromycin-resistant colonies only grew in tetracycline-supplemented medium. Using a series of primers that uniquely matched the upstream and downstream regions (P1-P6 in Table S1 ), the knockout strain was validated by PCR; a 1.3-kb amplified fragment in the wild-type strain was replaced with a 1.0-kb fragment in hygromycin-resistant colonies (Lane 1-3 in Fig. 1B) . Moreover, western blotting showed that the expression level of MSMEG_0129 protein was proportional to the tetracycline concentration in the culture medium (Fig. 1C) .
To further probe the dependence of bacterial growth on MSMEG_0129, the MSMEG_0129 complemented strain grown in the presence of tetracycline was inoculated into fresh medium without tetracycline. No bacterial growth was observed during the following 24 h. In contrast, bacteria grew normally in medium containing 20 ngÁmL À1 tetracycline, at rates comparable with the wild-type strain (Fig. 1D ). In addition, the growth rate seemed to be proportional to tetracycline concentration when the medium was supplemented with diluted tetracycline (Fig. 1E) . These data show solidly that the expression level of MSMEG_0129 is an essential factor for M. smegmatis growth.
To determine whether growth inhibition resulting from decreased expression of MSMEG_0129 was due to cell death or to arrest of cell division, parallel tests were performed. We first cultured the MSMEG_0129-complemented strain in medium containing tetracycline until the OD 600 was > 2.0. After removal of tetracycline by washing and dilution, harvested cells were separately diluted with a medium containing or not containing tetracycline to an OD 600 of 0.5 and cultured for 20 h. As expected, bacteria only showed growth in the presence of tetracycline. Harvested bacteria from both cultures were diluted to an OD 600 of 0.02, and inoculated again into fresh medium containing 20 ngÁmL À1 tetracycline before culturing for another 20 h. Bacteria grew in both cultures regardless of their source (Fig. 1F) , indicating that most bacteria could survive but not grow in the absence of tetracycline. These results thus show that insufficient expression of MSMEG_0129 inhibits M. smegmatis growth by blocking cell division rather than by causing cell death. Values in parentheses are statistics of the highest resolution shell.
Overall structure of MSMEG_0129 displays a fold similar to ARO/CYCs Recombinant MSMEG_0129 protein purified after expression in E. coli was subjected to crystallization trials. A crystal obtained under a sodium formate condition in 50 days after drop setup diffracted to 1.95 A [36] . The structure was determined by means of molecular replacement using ZhuI (PDB entry 3TFZ) [29] as a search model, although the proteins share low sequence identity (19%). After phasing and remodeling, the structure was refined with reasonable statistics (Table 1) .
A dimer of MSMEG_0129 resides in the asymmetric unit, agreeing well with the elution profile obtained from size exclusion chromatography [36] . Almost the full-length sequence (residues 1-142) and three extra N-terminal amino acids remaining from the expression construct (residues À3 to À1) were well-defined in each subunit exhibiting a helix-grip fold similar to known ARO/CYC structures [17, 18, 28, 29] . A deep pocket with a wide opening is encircled by a twisted sevenstranded antiparallel b-sheet, a long C-terminal a-helix (a3), and two short helices (a1 and a2) sandwiched between b1 and b2 ( Fig. 2A) . The two protein monomers are related by a noncrystallographic twofold axis, but with a dimerization mode that differs from ZhuI [29] . Despite the small interface area (446 A 2 of subunit A and 454 A 2 of subunit B), contributed mainly from one edge of the b-sheet, the dimeric architecture of MSMEG_0129 is stably maintained via five hydrogen bonds, with two salt bridges formed between R49 and D81 ( Fig. 2A) .
The potential ligand-binding pocket in MSMEG_0129 shows good plasticity
During structure refinement, a blob of F o À F c electron density contoured above 3.0 r was unexpectedly observed inside the pocket of subunit B (Fig. 2B ), but not in subunit A, suggesting the presence of a smallmolecule compound with high occupancy. The density was reminiscent of that reported for a ZhuI structure that contained a crystallization component, CAPS, bound to its interior pocket [29] . We modeled components of purification buffers and the crystallization solution into the density in question, but all resulted in poor fitting. Its shape suggests that a compound comprising four 6-membered planar rings may be present. An experienced crystallographer suggested we model benzopinacol, a compound that contains four phenyl and two hydroxyl groups (personal communication via the CCP4 mailing system). The molecule displayed good fitting for all phenyls, but was imperfect for the hydroxyls. Since benzopinacol is often used as one of the basic units in the synthesis of plastic and the crystal of MSMEG_0129 had been grown in a plastic tray for 50 days, we reasoned that a plastic-dissociated benzopinacol derivative had fortuitously entered the interior pocket of subunit B, which was located in a different microenvironment from subunit A within the crystal. The undefined ligand in our structure is much bulkier than the compounds cocrystallized with ZhuI [29] , TcmN or WhiE [17] . Owing to the presence of such a bulky molecule, there is striking conformational divergence between the two subunits (rmsd of 1. 2 A on 142 C a atoms), particularly in the b-hairpin connecting b3 and b4 (Fig. 2C ). In comparison with subunit A, the hairpin loop was pushed away by 6.7
A from the interior pocket in subunit B, leading to considerable pocket enlargement and a wider opening (Fig. 2D,E) , which is reflected in higher B-factors of that hairpin and the long C-terminal helix (Fig. S1) . The serendipitous entrapment of this compound in our structure indicates that the pocket in the START domain has good plasticity; a structural feature that has not been observed in previously reported structures.
Structural comparisons reveal MSMEG_0129 has distinctive pocket properties
The Dali server was used to search for structural neighbors of MSMEG_0129. The proteins with highest Z-scores are TTHA0849 (rmsd = 1.9 A), a hypothetical protein of unknown function from Thermus theromphilus [44] , ZhuI from Streptomcyes sp. R1128 (rmsd = 1.9 A) and TcmN from Streptomyces glaucescens (rmsd = 2.1 A). Structure-based sequence alignment (Fig. 3A) shows that MSMEG_0129 is very similar to ZhuI and TcmN in structural topology even though it shares low sequence identity with them (Fig. 3A) . Consistent with this, the overall structure of these proteins overlay well, except that the long C-terminal helix shows a slight but visible difference in length and orientation (Fig. 3B) .
Pocket comparison, however, revealed significant differences among the three structures. While the pocket in subunit A of MSMEG_0129 is much smaller than that in subunit B, it is of comparable size to that of TcmN and markedly larger than that of ZhuI (Fig. 3C ). In addition, there is only one small opening in the ZhuI pocket, but two openings in the other two structures. Twenty (i.e., more than 70%) of the amino acid residues located within the pocket in MSMEG_0129 are hydrophobic (W27, I31, L48, L50,  V52, I54, F61, V65, I73, L77, F83, F90, L102, V104,  L106, V108, V119 , L122, A123, L130) (Fig. S2A) while only nine are hydrophilic (Y24, N28, E30, T63, T75, H82, Q86, Q88, T126) (Fig. S2B ). This percentage is higher than that in ZhuI or TcmN (Tables S2 and S3) . Notably only two charged residues, E30 and H82, are present within the pocket, much fewer than observed in known ARO/CYCs.
Several polar or charged residues in ZhuI and TcmN, for example, R66, H109, and D146 in ZhuI, and Y35, R82, R69 in TcmN, are assumed to play catalytic roles in polyketide cyclization and aromatization [18, 29] . These amino acids, however, are all replaced with hydrophobic residues in MSMEG_0129 ( Fig. 3A and Tables S2 and S3 ). The poor conservation of these putative catalytic residues implies that MSMEG_0129 may not have ARO/CYC activity, or if it has, that its catalytic mechanism must be distinct from known ARO/CYC enzymes.
Docking simulations do not suggest MSMEG_0129 is a candidate ARO/CYC
It is difficult to obtain reaction intermediates generated in the process of polyketide synthesis; to date no cocrystal structures of an ARO/CYC in complex with a polyketide intermediate have been reported. Instead, docking of presumable intermediates to the interior pocket of an enzyme is a commonly used method to study potential reaction mechanisms [17, 29] . Here, we conducted comparative docking simulations using a protocol similar to that used in ZhuI, TcmN and WhiE ARO/CYC docking studies [17, 29] . Two bicyclic aromatic intermediates, A20 and A24 (Fig. S3) , generated in the C7-C16 and C9-C14 first-ring cyclization pathways, respectively, were docked to the pocket in subunit A of MSMEG_0129, TcmN, and ZhuI. The binding site of JRO in the WhiE structure (PDB entry 3TL1) [17] was used a reference position to direct docking trials.
The pockets in all three proteins are large enough to accommodate either A20 or A24 (Figs 4 and 5) , but both molecules displayed more flexible docking conformations in MSMEG_0129 than in ZhuI, consistent with the larger pocket space in our structure (Fig. 3C) . Analysis of the protein-compound interactions revealed a notable difference among these proteins. The aromatic bicycle in both docked molecules is sandwiched between a pair of Trp residues, that is, W65 and W108 in TcmN ( Figs 4B and 5B) or W62 and W93 in ZhuI (Figs 4C and 5C), and thereby an extended p-p conjugated resonance system is formed, which provides favorable interactions for ligand binding. Such a system, however, does not exist between the docked molecule and MSMEG_0129 because it lacks a similar tryptophan pair in its interior pocket. The only Trp residue, W27, is located at a nonconserved position close to the pocket bottom and beyond the interacting distance with the aromatic bicycles in A20 or A24 (Figs 4A and 5A ). These docking simulations infer that aromatic polyketides may not be the preferred ligands bound to MSMEG_0129 due to the lack of crucial interactions.
Notably, 11 hydrogen bonds were formed surrounding A24 in the MSMEG_0129 pocket, outnumbering those formed in the other two models (Fig. 5) , possibly due to its larger pocket space. All carbonyl oxygen atoms in the U-shaped polyketide chains are involved in hydrogen bonding with polar residues nearby (Fig. 5A) , generating specific interactions favorable for ligand binding. In contrast, A20 formed only four intermolecular hydrogen bonds with pocket residues in MSMEG_0129 (Fig. 4A) . This sharp divergence strongly implies that a molecule with a bulkier noncyclic structure would be a better vbinding ligand for MSMEG_0129. Considering the missing p-p interactions, we speculate that MSMEG_0129 may accommodate a compound with long linear chains rather than multiple aromatic cycles.
Discussion
Despite extensive immunological studies on Rv0164 from M. tuberculosis, identified as both a T-and B-cell antigen [6] [7] [8] [9] [10] , the biological function of this conserved mycobacterial protein is unknown. In this study, we performed genetic and structural studies on its close homolog, MSMEG_0129, in M. smegmatis in order to deduce the biological roles of Rv0164. The crystal structure of MSMEG_0129 revealed a fold very similar to that of ZhuI and TcmN (Fig. 3B) , leading us to speculate that this protein could be an ARO/ CYC.
A straightforward way to probe the enzymatic activity of MSMEG_0129 would be to perform biochemical assays. While type II PKSs from Streptomyces sp., including ARO/CYCs, are well studied, homologous enzymes from mycobacteria have never been identified before. Their substrates, products, and the enzymes catalyzing upstream/downstream reactions are completely unknown, making it impossible to build a reaction system similar to those used in biochemical studies of well-characterized ARO/CYC such as ZhuI, TcmN, and WhiE [17, 18, 29] . Determining the biochemical activity of MSMEG_0129 is thus unfortunately beyond our current grasp. Nonetheless, our analyses based on structural comparisons, docking simulations and genomic context of the encoding gene strongly suggest that MSMEG_0129 is a START superfamily member without enzymatic activity.
Three pieces of evidence support this speculation. Firstly, according to the catalytic mechanism proposed for characterized ARO/CYCs, the enzyme pocket should contain a conserved arginine (R66 in ZhuI and R82 in TcmN), serving as the general base required for aldol condensation during polyketide cyclization [18, 28, 29] . MSMEG_0129, however, lacks such a catalytic Arg residue in its pocket (Table S3 and Fig. 1B) , indicating that this protein cannot catalyze the reaction using the same mechanism, or more likely that it does not possess this catalytic activity at all. Secondly, as described above, in contrast to the 2-4 Trp residues located in the pocket of known ARO/CYC structures, the single pocket tryptophan (W27) in MSMEG_0129 is located far away from the aromatic compounds potentially bound to the pocket (Fig. S2B) , precluding the formation of critical p-p interactions and therefore being unfavorable for polyketide aromatization. Thirdly, neither the MSMEG_0129 nor Rv0164 encoding genes are located within a typical type II PKS gene cluster, such as that in the genomes of Streptomyces sp. typically comprising neighboring genes encoding ketosynthase-chain length factor heterodimer, acyl carrier protein, ketoreductase, cyclase, and aromatase [26, 45] . Genes adjacent to msmeg_0129 are not found among this list (Fig. 1A) .
In conclusion, MSMEG_0129, a novel member of the START domain superfamily, seems to have a function other than as an ARO or CYC. Since the expression of MSMEG_0129 is essential for bacterial growth (Fig. 1) , we suppose that this protein and its homolog in M. tuberculosis likely play an irreplaceable role during bacterial growth, for example, in lipid transfer during mycobacterial envelope synthesis.
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